0.670.690.64PFSP值<0.0001<0.001d0.0002<0.0001进展风险↓52%↓33%↓31%↓36%ORR(%)2250466424353851ORRP值<0.0001<0.001d0.00970.00541.Klenckeetal.ASCO2019.;2.JClinOncol.2009;27(30):4966-72;3.JClinOncol.2019;28(20):3239-47;4.Robertetal.ASCO2009a独立评审评估;bPFS在疾病进展前就进行非研究治疗方案的删失;c15mg/kg.q3w;d探索性P值P=紫杉醇;B=贝伐单抗;PL=安慰剂;D=多西他赛;X=卡培他滨;T/A=紫杉类/蒽环类贝伐珠单抗联合化疗PFS获益,但OS并未获益CancerTreatRev.2019;38(6):673-688雷莫芦单抗用于晚期乳腺癌的一线治疗Multicenter,randomized,double-blind,placebo-controlled,phase3trialHER2-negative,unresectable,locally-recurrentormetastaticbreastcancerNopriorchemotherapyorbiologictherapyforadvancedbreastcancerPrimaryendpoint:Investigator-AssessedPFSMackeyJRetal.SABCS2019.AbstractS5-04RANDOMIZATION2:1Docetaxel75mg/m2IVq3wksBlindRam10mg/kgIVq3wksDocetaxel75mg/eptableToxicityOrConsentWithdrawFollow-upforPDandforOSN=1144
全文预览